Revenue segments as reported by the company.

Product sales

Other revenues

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Research and development

Acquired in-process research and development

Selling, general and administrative

Other

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Amgen

Amgen, Inc. is a biotechnology company, which engages in the discovery, development, manufacture and marketing of human therapeutics. Its products include the following brands: Aranesp, Aimovig, KANJINTI, EVENITY, AMGEVITA, AVSOLA, BLINCYTO, MVASI, Corlanor, Enbrel, EPOGEN, IMLYGIC, Kyprolis, Neulasta, NEUPOGEN, Nplate, Parsabiv, Prolia, Repatha, Sensipar, Vectibix, Otezla, RIABNI, and XGEVA. The company was founded by William K. Bowes, Jr., Franklin Pitcher Johnson, Jr., George B. Rathmann, and Joseph Rubinfeld on April 8, 1980 and is headquartered in Thousand Oaks, CA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Amgen reports robust Q4 results, navigates pricing challenges for growth

Amgen's Q4 earnings call highlighted strong performance, innovative products, and strategic acquisitions driving growth. Challenges in pricing strategies and market dynamics require careful navigation. Opportunities in promising data, asset advancements, and access strategies position Amgen for future success.

Amgen reports robust Q1 performance, eyes growth in Asia-Pacific

Amgen's Q1 2023 earnings call highlighted strong performance, innovative R&D focus, and growth in key markets like Asia-Pacific.
Despite challenges with inventory issues and pricing dynamics, the company remains optimistic about long-term growth opportunities and biosimilar competitiveness.
Opportunities lie in addressing complex disorders like obesity, expanding market presence, and driving growth in key product franchises.
Overall, Amgen's strategic focus on performance, international expansion, and pipeline advancements positions the company for sustained growth and innovation.

Amgen reports robust Q2 earnings, eyes growth through strategic acquisitions

Amgen's strong Q2 performance, robust sales growth, and strategic acquisitions position the company for continued success.
While facing challenges in competitive markets and potential legal risks, Amgen's focus on innovation and portfolio expansion presents growth opportunities.
With a solid financial outlook, increased R&D investments, and a focus on shareholder returns, Amgen remains well-positioned for future growth.
Updates on key products, positive trial results, and strategic initiatives underscore Amgen's commitment to advancing healthcare and driving value creation.

Amgen reports revenue and earnings growth, eyes AI for innovation

Amgen's Q3 performance showed revenue and earnings growth, driven by strong global volume and record sales for key medicines. The company's pipeline progress and strategic focus on R&D highlight a commitment to innovation and future growth. While challenges exist around acquisition integration and market competition, Amgen is poised for continued success through the end of the decade and beyond.

Amgen reports record sales in Q4 2023, eyes rare diseases

Amgen's Q4 2023 performance was robust, driven by record sales and strategic acquisitions.
Despite short-term challenges like tax payments impacting cash flow, the company remains confident in its long-term growth trajectory.
Opportunities lie in expanding the rare disease portfolio, advancing R&D initiatives, and exploring new therapeutic areas.
Overall, Amgen's strong financials, diverse pipeline, and focus on innovation position it well for sustained growth and global impact.

Amgen reports strong Q1 growth, eyes new markets and innovations

Amgen's Q1 2024 performance reflects strong sales growth, financial resilience, and continued momentum in key product segments, positioning the company for future success.
Despite challenges in competitive differentiation, product launches, and regulatory complexities, Amgen's strategic strengths in innovation, manufacturing, and market expansion offer a solid foundation for growth.
The company's focus on addressing unmet medical needs, exploring new therapeutic areas, and advancing pipeline candidates underscores its commitment to driving patient impact and capturing market opportunities.
With a robust financial outlook, ongoing Phase III trials, and a proactive approach to product development, Amgen is well-positioned to achieve its revenue targets, drive innovation, and deliver value to shareholders.

Amgen reports strong Q2 earnings, eyes growth in diverse markets

Amgen's Q2 2024 earnings call highlighted robust revenue growth, strong sales performance, and promising pipeline developments across various therapeutic areas.
While facing challenges in market dynamics and product differentiation, Amgen's strategic focus on rare diseases and innovative therapies positions it well for future growth.
With a clear outlook on capital allocation, continued expansion in endocrinology, and opportunities in the obesity market, Amgen remains poised for sustained success.

Amgen reports strong Q3 earnings and outlines growth strategies

Amgen's Q3 2024 earnings call highlighted robust financial performance, progress in pipeline development, and strategic initiatives for future growth. With a strong revenue outlook and focus on innovation, Amgen remains well-positioned in the biopharmaceutical industry.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Amgen, Inc. is a biotechnology company, which engages in the discovery, development, manufacture, and marketing of human therapeutics. It operates through Human Therapeutics segment. The company was founded by William K. Bowes, Jr., Franklin Pitcher Johnson, Jr., George B. Rathmann, and Joseph Rubinfeld on April 8, 1980 and is headquartered in Thousand Oaks, CA.

AbbVie

Biogen

Bristol-Myers

Gilead Sciences

iShares Nasdaq Biotechnology ETF

Novartis

Pfizer

Vertex Pharmaceuticals

SPDR S&P Biotech ETF

Drug developers took center stage as the world looks to these companies to deliver an answer to COVID-19.

4 Reasons Drug Stocks Are a Buy Right Now

Eli Lilly

Merck

Mylan

Several pharma & biotech companies announce their plan to fight coronavirus pandemic and state anticipated unfavorable impact of the outbreak on their business.

Pharma, Biotech Players Step Up Efforts Against Coronavirus

Amneal Pharmaceuticals

Mirati Therapeutics

Viking Therapeutics

Verastem

Healthcare bargain hunters can find good values in quality low-priced stocks.

Top Drug Stocks Under $5

Amgen: A Healthy And Defensive Pick In COVID-19 Times

Moderna

Regeneron Pharmaceuticals

Biotech companies have outperformed the general market -- and there are plenty of reasons to remain optimistic.

4 Reasons Biotech Stocks Are a Buy Right Now

CRISPR Therapeutics

Editas Medicine

Innoviva

Biotech stocks pulled off an impressive rally to finish 2019 strong. These names in the industry are looking to do the same in 2020.

7 Biotech Stocks to Buy and Hold in 2020

Both companies offer solid products and pipelines, but only one presents a buy-right-now case.

Better Buy: Biogen vs. Amgen

Takeda Pharmaceutical

Lawmakers have for years been concerned the U.S. is too reliant on foreign manufacturing of medicine.

Lawmakers pressure Big Pharma on drug supply chains amid coronavirus outbreak

Amgen (AMGN) boasts a strong biosimilars portfolio, which can drive long-term growth. Amgen is also progressing with its pipeline while regularly pursuing business development deals.

Is Amgen (AMGN) Truly One of the Best Biotech Stocks to Own?

General Dynamics

Hess

Philip Morris

Verizon

Verizon Communications Inc 5.9 % Notes 2014-15.2.54 Sr

Daily Dividend Report: General Dynamics, Hess, Verizon Communications, Amgen, Philip Morris

Amgen shows improving price performance, earning an upgrade to its IBD Relative Strength Rating
The post Amgen Stock Strength Climbs Amid 'New Product Driven' Growth appeared first on Investor's Business Daily.

Amgen Stock Strength Climbs Amid 'New Product Driven' Growth

Amgen (AMGN) reported earnings 30 days ago. What's next for the stock?

Why Is Amgen (AMGN) Down 11.7% Since Last Earnings Report?

Veeva Systems

Coronavirus has many investors looking for a health stock bump, but these names are great for the long haul.

3 Top Healthcare  Stocks to Buy Right Now

A Relative Strength Rating upgrade for Amgen shows improving technical performance. Will it continue?

IBD Rating Upgrades: Amgen Shows Improved Technical Strength

Cytokinetics

Data Monitoring Committee Recommends Phase 3 Clinical Trial of Omecamtiv Mecarbil in Patients with Heart Failure Continue without Changes

Amgen, Cytokinetics and Servier Announce Continuation of GALACTIC-HF Following Planned Interim Analysis

Revolution Medicines

The share price of a clinical-stage oncology company that went public just last week has climbed more than 70% on hopes that it can develop drugs to transform the way cancer is treated.

Revolution Medicines Joins Amgen and Mirati in Quest for New Type of Cancer Drugs

Amgen, Biogen, and Gilead Sciences have each transformed their early investors.

3 Biotech Stocks That Made Early Shareholders Millionaires

Amgen’s pipeline and an oncology collaboration in China are reasons to believe the recent revenue slowdown may be transient.

Is Amgen a Stock to Buy?

Amgen sees its Relative Strength Rating hit the 80-plus level ahead of key drug data results.
The post Amgen Stock Relative Strength Climbs Ahead Of Key Drug Data appeared first on Investor's Business Daily.

Amgen Stock Relative Strength Climbs Ahead Of Key Drug Data

Investors worried about a slowdown in revenue as biosimilars are rivals to older drugs.

Why Amgen Stock Dropped 10.4% in January

Amgen stock is facing concerns that its adjusted earnings will slide in 2020. Is it time to buy shares of the biotech company?

The Biggest Biotech Is Facing Profitability Worries — Is It Time To Buy Amgen Stock?

At least one of these bets is already looking like a smart move.

Amgen Is Making 3 Big Bets -- Will They Pay Off for Investors?

Amgen, Inc.'s (NASDAQ: AMGN) disappointing 2020 EPS guidance issued Thursday spooked investors, leading to a pullback in the stock.

Amgen Analysts Sidelined After Q4 Report, Say Valuation Reflects Growth Potential

Amgen's fourth-quarter earnings contained mostly good news, but shareholders clearly wanted more out of the blue-chip drugmaker.

Amgen's Shares Slip on Soft Guidance. Time to Buy?

Amgen (AMGN) stock declines despite better-than-expected fourth-quarter 2019 results. Its 2020 earnings guidance falls short of expectations.

News for Amgen Stock (AMGN)